Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior

Jan 23 2018

• By Mandy Jackson

Accept - Refuse_529502731_1200.jpg

Related Content

Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage

Nov 02 2017

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

Dec 02 2017

Related Companies

Apple Tree Partners

Indivior plc

Additional Topics

Complete Response Letters Business Strategies Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.